Caplan SN, Berkman EM. Letter: Protamine sulfate and sh allergy. N Engl J Med. 1976;295(3):172. 101. Lytle BW, Cosgrove DM, Taylor PC, et al. Reoperations for valve surgery: perioperative mortality and determinants of risk for 1,000 patients, 1958-1984. Ann Thorac Surg. 1986;42(6):632-643. 102. Cooney A, Mann TJ. Recent experiences with hexadi- methrine for neutralizing heparin after cardiopulmonary bypass. Anaesth Intensive Care. 1999;27(3):298-300. 103. Kikura M, Lee MK, Levy JH. Heparin neutralization with methylene blue, hexadimethrine, or vancomycin after car- diopulmonary bypass. Anesth Analg. 1996;83(2):223-227. 104. Despotis GJ, Summer eld AL, Joist JH, et al. In vitro reversal of heparin effect with heparinase: evaluation with whole blood prothrombin time and activated partial 2012 American College of Chest Physicians by Kimberly Henricks on February 10, 2012 chestjournal.chestpubs.org Downloaded from e40S Parenteral Anticoagulants Conference XXXI on laboratory monitoring of anticoagu- lant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med. 1998;122(9):799-807. 139. Boneu B. Low molecular weight heparin therapy: is moni- toring needed? Thromb Haemost. 1994;72(3):330-334. 140. Boneu B, de Moerloose P. How and when to monitor a patient treated with low molecular weight heparin. Semin Thromb Hemost. 2001;27(5):519-522. 141. Becker RC, Spencer FA, Gibson M, et al; TIMI 11A Investigators. In uence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non- ST-segment elevation acute coronary syndromes. Am Heart J. 2002;143(5):753-759. 142. Roman MJ, Shanker BA, Davis A, et al. Prevalence and cor- relates of accelerated atherosclerosis in systemic lupus ery- thematosus. N Engl J Med. 2003;349(25):2399-2406. 143. Wilson SJ, Wilbur K, Burton E, Anderson DR. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis. 2001;31(1):42-48. 144. 